<p>Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 获取免费报告）获得了目前覆盖该公司的八位分析师的共识推荐为 “适度买入”，MarketBeat 报告称。一位研究分析师对该股票给予了卖出推荐，一位给予了持有推荐，五位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，对该股票发布评级的经纪公司平均 12 个月的目标价格为 13.60 美元。</p>
<p>获取 <strong>Orchestra BioMed</strong> 警报：</p>
<p>一些研究公司最近对 OBIO 发表了评论。巴克莱将 Orchestra BioMed 的目标价格从 12.00 美元下调至 11.00 美元，并在 11 月 12 日的研究报告中对该公司给予了 “增持” 评级。Cowen 于 12 月 10 日的报告中开始覆盖 Orchestra BioMed 的股票，并给予该公司 “买入” 评级。TD Cowen 于 12 月 10 日的研究报告中开始覆盖 Orchestra BioMed 的股票，给予了 “买入” 评级和 15.00 美元的目标价格。Chardan Capital 在 11 月 13 日的报告中重申了 “买入” 评级，并对 Orchestra BioMed 的股票设定了 20.00 美元的目标价格。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Orchestra BioMed 股票的 “卖出（e+）” 评级。</p>
<p><strong>获取我们最新的 Orchestra BioMed 研究报告</strong></p>
<h2>Orchestra BioMed 的机构交易</h2>
<p>机构投资者最近对该公司的持仓进行了调整。Alyeska Investment Group L.P. 在第三季度收购了价值 3,386,000 美元的 Orchestra BioMed 新头寸。Pathstone Holdings LLC 在第三季度购买了价值 2,495,000 美元的 Orchestra BioMed 新股份。先锋集团（Vanguard Group Inc.）在第三季度将其在 Orchestra BioMed 的持仓提高了 28.0%。先锋集团目前拥有 1,481,875 股该公司股票，价值 3,675,000 美元，此前在上个季度又购买了 324,558 股。AMH Equity Ltd 在第三季度购买了价值约 412,000 美元的 Orchestra BioMed 新头寸。最后，Knott David M Jr 在第二季度购买了价值约 268,000 美元的 Orchestra BioMed 新头寸。53.20% 的股票由机构投资者和对冲基金持有。</p>
<h2>Orchestra BioMed 股票上涨 3.9%</h2>
<p>Orchestra BioMed 股票在周五开盘价为 4.31 美元。该公司的 50 日简单移动平均为 4.35 美元，200 日简单移动平均为 3.39 美元。公司的债务与股本比率为 0.32，速动比率为 4.72，流动比率为 4.73。Orchestra BioMed 的 52 周低点为 2.20 美元，52 周高点为 6.16 美元。该公司的市值为 2.4339 亿美元，市盈率为-2.37，贝塔值为 0.63。</p>
<p>Orchestra BioMed（NASDAQ:OBIO - 获取免费报告）最后一次发布财报是在 11 月 10 日，报告显示该公司季度每股收益为（0.40）美元，低于分析师共识预期的（0.38）美元，差额为（0.02）美元。该公司季度收入为 86 万美元，而分析师预期为 74 万美元。Orchestra BioMed 的净利润率为-2,665.05%，股本回报率为-320.09%。作为一个整体，股票分析师预测 Orchestra BioMed 在当前财政年度的每股收益将为-1.66。</p>
<h2>Orchestra BioMed 公司简介</h2>
<p>（获取免费报告）</p>
<p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究专注于新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
<p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心密切合作，以推进其项目。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，而不是 Orchestra BioMed</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>在 2026 年 5 月 20 日之前购买这只 2 美元的黄金股票</li>
<li>3 个被忽视的扣除项，帮助潜在减少资本利得税</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Orchestra BioMed 吗？</h2>
<p>在你考虑 Orchestra BioMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Orchestra BioMed 并不在名单上。</p>
<p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OBIO

<p>Orchestra BioMed Holdings, Inc.（纳斯达克代码：OBIO）获得了八位分析师的 “适度买入” 共识推荐。平均十二个月的目标价格为 13.60 美元。最近的评级包括一位分析师的卖出评级、一位分析师的持有评级、五个买入评级和一个强烈买入评级。机构投资者持有该股票的 53.20%。股票开盘价为 4.31 美元，市值为 2.4339 亿美元。该公司报告的季度每股收益为（0.40 美元），未达到预期，收入为 86 万美元。Orchestra BioMed 专注于开发针对炎症和肿瘤疾病的治疗方案</p>

<p>Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the eight analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.60.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 获取免费报告）获得了目前覆盖该公司的八位分析师的共识推荐为 “适度买入”，MarketBeat 报告称。一位研究分析师对该股票给予了卖出推荐，一位给予了持有推荐，五位给予了买入推荐，还有一位给予了强烈买入推荐。在过去一年中，对该股票发布评级的经纪公司平均 12 个月的目标价格为 13.60 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Orchestra BioMed</strong> 警报：</p>
</div><p>A number of research firms have recently commented on OBIO. Barclays cut their price objective on Orchestra BioMed from $12.00 to $11.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, November 12th. Cowen began coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a &#34;buy&#34; rating for the company. TD Cowen began coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a &#34;buy&#34; rating and a $15.00 price objective for the company. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th.</p>
<div class="lb-trans"><p>一些研究公司最近对 OBIO 发表了评论。巴克莱将 Orchestra BioMed 的目标价格从 12.00 美元下调至 11.00 美元，并在 11 月 12 日的研究报告中对该公司给予了 “增持” 评级。Cowen 于 12 月 10 日的报告中开始覆盖 Orchestra BioMed 的股票，并给予该公司 “买入” 评级。TD Cowen 于 12 月 10 日的研究报告中开始覆盖 Orchestra BioMed 的股票，给予了 “买入” 评级和 15.00 美元的目标价格。Chardan Capital 在 11 月 13 日的报告中重申了 “买入” 评级，并对 Orchestra BioMed 的股票设定了 20.00 美元的目标价格。最后，Weiss Ratings 在 10 月 8 日的研究报告中重新发布了对 Orchestra BioMed 股票的 “卖出（e+）” 评级。</p>
</div><p><strong>Get Our Latest Research Report on Orchestra BioMed</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Orchestra BioMed 研究报告</strong></p>
</div><h2>Institutional Trading of Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的机构交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC purchased a new stake in shares of Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. raised its position in shares of Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock valued at $3,675,000 after buying an additional 324,558 shares during the last quarter. AMH Equity Ltd purchased a new position in shares of Orchestra BioMed in the third quarter worth about $412,000. Finally, Knott David M Jr purchased a new position in shares of Orchestra BioMed in the second quarter worth about $268,000. 53.20% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该公司的持仓进行了调整。Alyeska Investment Group L.P. 在第三季度收购了价值 3,386,000 美元的 Orchestra BioMed 新头寸。Pathstone Holdings LLC 在第三季度购买了价值 2,495,000 美元的 Orchestra BioMed 新股份。先锋集团（Vanguard Group Inc.）在第三季度将其在 Orchestra BioMed 的持仓提高了 28.0%。先锋集团目前拥有 1,481,875 股该公司股票，价值 3,675,000 美元，此前在上个季度又购买了 324,558 股。AMH Equity Ltd 在第三季度购买了价值约 412,000 美元的 Orchestra BioMed 新头寸。最后，Knott David M Jr 在第二季度购买了价值约 268,000 美元的 Orchestra BioMed 新头寸。53.20% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Orchestra BioMed Trading Up 3.9%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上涨 3.9%</h2>
</div><p>Shares of Orchestra BioMed stock opened at $4.31 on Friday. The firm has a 50-day simple moving average of $4.35 and a two-hundred day simple moving average of $3.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a fifty-two week low of $2.20 and a fifty-two week high of $6.16. The company has a market cap of $243.39 million, a P/E ratio of -2.37 and a beta of 0.63.</p>
<div class="lb-trans"><p>Orchestra BioMed 股票在周五开盘价为 4.31 美元。该公司的 50 日简单移动平均为 4.35 美元，200 日简单移动平均为 3.39 美元。公司的债务与股本比率为 0.32，速动比率为 4.72，流动比率为 4.73。Orchestra BioMed 的 52 周低点为 2.20 美元，52 周高点为 6.16 美元。该公司的市值为 2.4339 亿美元，市盈率为-2.37，贝塔值为 0.63。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. As a group, equities analysts predict that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Orchestra BioMed（NASDAQ:OBIO - 获取免费报告）最后一次发布财报是在 11 月 10 日，报告显示该公司季度每股收益为（0.40）美元，低于分析师共识预期的（0.38）美元，差额为（0.02）美元。该公司季度收入为 86 万美元，而分析师预期为 74 万美元。Orchestra BioMed 的净利润率为-2,665.05%，股本回报率为-320.09%。作为一个整体，股票分析师预测 Orchestra BioMed 在当前财政年度的每股收益将为-1.66。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究专注于新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心密切合作，以推进其项目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>Do not delete, read immediately</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
<li>3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Orchestra BioMed</li>
<li>请勿删除，立即阅读</li>
<li>没有人告诉你的 100 万亿美元的人工智能故事</li>
<li>如果你在美国银行账户中存现金……请立即阅读</li>
<li>在 2026 年 5 月 20 日之前购买这只 2 美元的黄金股票</li>
<li>3 个被忽视的扣除项，帮助潜在减少资本利得税</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Orchestra BioMed 吗？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Orchestra BioMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Orchestra BioMed 并不在名单上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Orchestra BioMed 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Orchestra BioMed Holdings, Inc.（NASDAQ 代码：OBIO）被分析师一致推荐为 “适度买入”